Caprock Group LLC Acquires Shares of 44,359 Tandem Diabetes Care, Inc. $TNDM

Caprock Group LLC acquired a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 44,359 shares of the medical device company’s stock, valued at approximately $555,000. Caprock Group LLC owned approximately 0.07% of Tandem Diabetes Care at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. CWM LLC lifted its position in Tandem Diabetes Care by 262.6% during the 2nd quarter. CWM LLC now owns 2,796 shares of the medical device company’s stock worth $52,000 after acquiring an additional 2,025 shares in the last quarter. CoreCap Advisors LLC raised its stake in shares of Tandem Diabetes Care by 270.3% during the third quarter. CoreCap Advisors LLC now owns 4,751 shares of the medical device company’s stock valued at $58,000 after purchasing an additional 3,468 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Tandem Diabetes Care by 186.9% during the second quarter. Nisa Investment Advisors LLC now owns 4,171 shares of the medical device company’s stock worth $78,000 after purchasing an additional 2,717 shares in the last quarter. 180 Wealth Advisors LLC purchased a new position in shares of Tandem Diabetes Care in the third quarter valued at $126,000. Finally, Praxis Investment Management Inc. acquired a new stake in Tandem Diabetes Care during the 3rd quarter valued at $150,000.

Tandem Diabetes Care Stock Down 0.6%

Shares of NASDAQ:TNDM opened at $18.84 on Wednesday. The company’s fifty day moving average is $20.95 and its two-hundred day moving average is $16.92. The company has a debt-to-equity ratio of 2.33, a quick ratio of 1.90 and a current ratio of 2.44. Tandem Diabetes Care, Inc. has a 1-year low of $9.98 and a 1-year high of $35.12. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -6.18 and a beta of 1.68.

Analyst Upgrades and Downgrades

TNDM has been the topic of a number of recent analyst reports. Mizuho boosted their price objective on shares of Tandem Diabetes Care from $18.00 to $21.00 and gave the stock a “neutral” rating in a report on Wednesday, December 17th. Wells Fargo & Company increased their price target on Tandem Diabetes Care from $13.00 to $14.00 and gave the company an “equal weight” rating in a report on Friday, November 7th. Barclays raised their price objective on Tandem Diabetes Care from $51.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, November 10th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 target price on shares of Tandem Diabetes Care in a research report on Friday, January 9th. Finally, Stifel Nicolaus increased their target price on Tandem Diabetes Care from $16.00 to $20.00 and gave the company a “hold” rating in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $24.35.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.